retatrutide trial dose Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide trial results today Today

Indications / Uses Semaglutide is used to help adults with obesity, or adults with overweight who also have weight-related medical problems, to effectively lose excess body weight and maintain the weight loss

Diarrhea affects up to 20% of GLP-1 users during the first weeks of treatment

Discover how Retatrutide works through its triple-pathway mechanism (GLP-1, GIP, glucagon), how it affects metabolism, and when results may begin.

Simultaneously targets GLP-1, GIP, and Glucagon pathways for amplified fat-burning, insulin sensitivity, and appetite regulation

By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic, Wegovy, and Mounjaro, known as GLP-1 receptor agonists, are now widely used to treat type 2 diabetes and obesity

With a plethora of mixed opinions about whether or not they should be prescribed and a good amount of misinformation about side effects and risks, it can be a highly political and confusing landscape